{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:19Z","timestamp":1789545619039,"version":"build-2803163510"},"reference-count":24,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To analyze the clinical efficacy of anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) therapy in treatment of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, we describe cases of refractory SAPHO syndrome and review cases treated with anti-TNF-\u03b1 reported in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We describe 6 cases of patients with SAPHO syndrome treated with anti-TNF-\u03b1 between 2004 and 2008. Therapeutic response was evaluated according to improvement in pain score, amelioration of disease activity, and improvement in function. The efficacy of treatment was considered to be reduced need for analgesics and\/or antiinflammatory therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>In our series, 4 patients received infliximab, 1 etanercept, and 1 adalimumab. These treatments brought clinical response in 4 patients (66.6%): response was sustained with infliximab in 1 case for 7 months; with adalimumab in another case for 22 months; and with etanercept in 2 cases for 1 and 42 months, respectively. In contrast, 2 other patients showed no response to infliximab. Improvement was initially temporary after infusions 1 and 2, then pain recurred at Week 14. Skin lesions were healed in 3 of 4 cases, but recurred or worsened in 2 cases, after infusion 2 of infliximab. Treatment was generally well tolerated. Paradoxical psoriasis was noted in 2 cases and urticaria in 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Given our results and those from the literature, TNF-\u03b1 blockers should be considered in the therapeutic strategy of refractory cases of SAPHO syndrome, despite their effect seeming less impressive than in other spondyloarthropathies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.091086","type":"journal-article","created":{"date-parts":[[2010,5,15]],"date-time":"2010-05-15T20:14:54Z","timestamp":1273954494000},"page":"1699-1704","source":"Crossref","is-referenced-by-count":97,"title":["Tumor Necrosis Factor-\u03b1 Blockers in SAPHO Syndrome: Table 1."],"prefix":"10.3899","volume":"37","author":[{"given":"KAOUTHER","family":"BEN ABDELGHANI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DELPHINE GERARD","family":"DRAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACQUES-ERIC","family":"GOTTENBERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACQUES","family":"MOREL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEAN","family":"SIBILIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BERNARD","family":"COMBE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2010,5,15]]},"reference":[{"key":"2018112909233969000_37.8.1699.1","first-page":"187","article-title":"Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases [French]","volume":"54","author":"Chamot","year":"1987","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"2018112909233969000_37.8.1699.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(99)80027-4"},{"key":"2018112909233969000_37.8.1699.3","doi-asserted-by":"publisher","DOI":"10.1186\/ar2812"},{"key":"2018112909233969000_37.8.1699.4","doi-asserted-by":"publisher","DOI":"10.1186\/ar2837"},{"key":"2018112909233969000_37.8.1699.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh149"},{"issue":"Suppl 63","key":"2018112909233969000_37.8.1699.6","first-page":"62","article-title":"Infliximab therapy in 15 patients with psoriatic arthritis (PsA) [abstract]","volume":"28","author":"Brockbank","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909233969000_37.8.1699.7","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200202000-00002"},{"key":"2018112909233969000_37.8.1699.8","first-page":"424","article-title":"Is SAPHO a spondylarthropathy? A vasculopathy? Report of a case","volume":"64","author":"Boonen","year":"1997","journal-title":"Rev Rhum Engl Ed"},{"key":"2018112909233969000_37.8.1699.9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0274-6"},{"key":"2018112909233969000_37.8.1699.10","first-page":"91","article-title":"Ent\u00c3\u00a9rocolopathies chroniques et syndrome SAPHO (8 observations)","volume":"59","author":"Kahn","year":"1992","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"2018112909233969000_37.8.1699.11","first-page":"661","article-title":"Etude r\u00c3\u00a9trospective de 72 cas de SAPHO avec un suivi moyen de 14 ans","volume":"61","author":"Bouchaud-Chabot","year":"1994","journal-title":"Rev Rhum Engl Ed"},{"key":"2018112909233969000_37.8.1699.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.22087"},{"key":"2018112909233969000_37.8.1699.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.10539"},{"key":"2018112909233969000_37.8.1699.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.375"},{"key":"2018112909233969000_37.8.1699.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.006"},{"key":"2018112909233969000_37.8.1699.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2206"},{"key":"2018112909233969000_37.8.1699.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei221"},{"key":"2018112909233969000_37.8.1699.18","first-page":"250","article-title":"Infliximab in the treatment of SAPHO syndrome: clinical experience and MRI response [abstract]","volume":"62","author":"Widmer","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"2018112909233969000_37.8.1699.19","first-page":"S621A","article-title":"Successful treatment of SAPHO syndrome with infliximab. A case report [abstract]","volume":"48","author":"Asmussen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2018112909233969000_37.8.1699.20","first-page":"388","article-title":"Successful treatment of refractory SAPHO syndrome with infliximab [abstract]","volume":"63","author":"Kyriazis","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2018112909233969000_37.8.1699.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.004"},{"key":"2018112909233969000_37.8.1699.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0767-y"},{"key":"2018112909233969000_37.8.1699.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"2018112909233969000_37.8.1699.24","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328133f57b"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.091086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T12:42:50Z","timestamp":1543495370000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.091086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,15]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,8,1]]},"published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.3899\/jrheum.091086"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.091086","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,15]]}}}